Korea Celltrion Healthcare, the marketing arm of the biopharmaceutical company Celltrion won a huge deal in France last Friday (2nd November 2018) with big tenders for Herzuma, a biosimilar of Roche’s blockbuster breast cancer treatment Herceptin. Herzuma, with indications for positive metastatic breast cancer, early cancer, and metastatic gastric cancer…
Innovation Buck Dossey, an expert in digital marketing and audience manager at Adobe, discusses consumer needs in healthcare and the importance of adopting a digital health strategy. Joining the digital transformation race today means that many companies will have to transform to become digitally agile. While the topic of digital transformation permeates…
Korea Korea is fast becoming a big player in the pharmaceutical industry, especially within the biotech arena. With 4% of the total pipelines in the world, the country is showing strong R&D capabilities and fierce ambitions for growth. Korea is now the 3rd largest pharma region in Asia, with a forecasted…
Spain One of the unique aspects of the system is the fragmentation linked to the country’s 17 autonomous regions The Spanish healthcare system performance is ranked as 7th in the world by the World Health Organization (WHO), beating countries such as Japan, the Netherlands, United Kingdom, and the United States. Additionally,…
UK With more than 25 years pharmaceutical industry experience, Ian Chamberlain provides training to help pharma salespeople talk to customers and provides sales managers with software to help pharma companies intelligently listen to the dialogue. As an insider, Ian breaks down the changing role of medical salespeople, from “Tell Sell” to “Intelligent…
France Oliver Brandicourt, Sanofi’s CEO has kept his promise to steer the company back on the path to growth. This change in fortune comes after the French Pharma giant suffered losses due to competition to its diabetes and cardiovascular franchises. The growth is largely down to Dupixent — a drug for use…
Korea Korean Pharma company, Hanmi has won orphan drug status this week from the US Food and Drug Administration (FDA) for HM43239, a drug for the treatment of acute myeloid leukaemia (AML). The endorsement of FDA’s Orphan Drug Designation (ODD) — invented to smooth the development of therapies for life-threatening…
France As the UK prepares to leave the European Union in March 2019, stakeholders across the European life sciences industry are busy preparing for Brexit’s potential impact on their operations. In France, the Agence Nationale de Sécurité du Médicament et des Produits de Santé (ANSM) – the country’s drug regulator –…
Cyprus With a population of just 1.2 million and a proportionately small pharmaceutical market by EU standards, Cyprus is often overlooked as a healthcare and life sciences investment destination. However, with the island now on the road to economic recovery following the EUR ten billion IMF-ECB-EU troika bailout in 2013, an…
France Ipsen CEO David Meek provides a fascinating look into the French pharmaceutical ecosystem, Ipsen’s bold global expansion plans, its R&D transformation, and the exciting changes to come. From our roots as a French company, we have blossomed into a growing international player within the areas of oncology, neuroscience and…
Mexico Cristobal Thompson is the Executive Director at AMIIF (Asociacion Mexicana de Industrias de Investigacion Farmaceutica). The AMIIF represents more than 60 global companies with the aim of contributing to improving health in Mexico through innovative medicine. Here he discusses the new Alma-Ata Declaration that focuses on primary care and work at…
Algeria A sudden imposition of import restrictions on pharmaceuticals in 2017 has pushed several multinational companies to establish local production facilities in Algeria. However, the localization process can be fraught both for companies that establish direct manufacturing footprints via joint ventures and those that employ the services of local contract manufacturers.…
See our Cookie Privacy Policy Here